Search
MLN-977
go.drugbank.com/drugs/DB05431ExperimentalIt is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalLumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. … Results published from the CLL clinical trial failed to meet primary endpoints.
Phosphorus P-32
go.drugbank.com/drugs/DB14551InvestigationalEmitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular
Betaprodine
go.drugbank.com/drugs/DB01473ExperimentalIllicitAn opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.
Adenosine 5'-phosphosulfate
go.drugbank.com/drugs/DB03708InvestigationalThe initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.
Chlorphentermine
go.drugbank.com/drugs/DB01556ApprovedIllicitWithdrawnIt has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMedetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedThe drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. … In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer.
Categories: Analgesics, Non-NarcoticEtesevimab
go.drugbank.com/drugs/DB15897Investigationalprogressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for
Typhoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalIt is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.
INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] Early _in vitro_ studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. … [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.
Synonyms: INO-4800 DNA Coronavirus Vaccine